UNSPSC 51271807: Hexylcaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C16H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V00NQ7SDYI, chemically known as 2-propanol, 1-(cyclohexylamino)-, benzoate (ester) but more generally known as hexylcaine hydrochloride, which bears US NIH Compound Identifier 10770. European Medicines Agency schedules Hexylcaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02518MIG.

Most nations, for tariff and trade purposes, schedule hexylcaine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, HEXYLCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Hexylcaine hydrochloride bears US NLM identifiers UMLS ID C0770371 and NCI Concept Code C65853. SMILES: CC(CNC1CCCCC1)OC(=O)C2CCCCC2.CL.

UNSPSC 51271807 Hexylcaine hydrochloride is a Commodity code covering local anesthetic pharmaceutical ingredients supplied through state and local cooperative purchasing vehicles. State and local governments acquire this and related generic multi-source pharmaceuticals through centralized procurement frameworks that establish master agreements with manufacturers, who then supply products to authorized wholesalers for distribution across participating facilities including hospitals, clinics, emergency services, and corrections departments. The issuing bodies are primarily state procurement offices administering multistate cooperative purchasing alliances and the member jurisdictions they serve — state departments, counties, cities, and special-purpose districts that draw on these contracts for pharmacy and medical supply operations.

Activity under this code centers on the Upper Midwest and Pacific Northwest. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products serving participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions. The RFP (S1070000015802) requires vendors to supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with proposals due March 26, 2026 and awarded contracts effective July 1, 2026. Evaluation criteria weigh price competitiveness at 75 percent, fixed pricing and compliance with administrative requirements at 10 percent and 5 percent respectively, EDI capability and 3 percent administrative fee acceptance at 5 percent each. Vendors must maintain contractual relationships with at least two of the three authorized wholesalers, certify cGMP and Drug Supply Chain Security Act compliance, and carry commercial general liability coverage of $5,000,000 per occurrence.